Right, that’s why they continue to lie about their US and FDA pathway. UK approval wont change much in terms of attractiveness towards generating free cash flow, but continue to pump. They have mislead shareholders around other regulatory applications as well as reimbursements in the UK.
They will get slapped with a lawsuit later this year. There is no hiding. Some of the shareholders that care about highest level of business ethics, execution, and importantly ROI will not tolerate this anymore. They (management) have been given enough leeway and benefit of doubt over the last decade or so.
Market Data 
Markets 
AI
